Resistance Training on Semaglutide: Muscle Loss
GLP-1 and Muscle
39%
Proportion of lean mass lost relative to total weight loss in larger semaglutide trials without structured exercise programs.
Bikou et al., Expert Opinion on Pharmacotherapy, 2024
Bikou et al., Expert Opinion on Pharmacotherapy, 2024
View as imageSemaglutide produces weight loss of 10-15% in most clinical trials. The problem is what that weight consists of. A systematic review by Bikou et al. (2024) found that lean mass reductions ranged from nearly 0% to 40% of total weight lost across six trials with 1,541 adults.[1] That range is enormous, and the question of whether resistance training on semaglutide can shift the ratio toward fat loss and away from muscle loss has become one of the most pressing practical questions in the GLP-1 era. For a broader look at the scope of this issue, the GLP-1 sarcopenia risk in older adults article covers why this matters so much for long-term health.
Key Takeaways
- Lean mass accounted for 26-40% of total weight lost in larger semaglutide trials without structured exercise (Bikou et al., 2024)
- The SEMALEAN study found lean mass declined 3 kg at 7 months but stabilized by 12 months, with grip strength improving 4.5 kg (Alissou et al., 2026)
- A case series showed patients doing resistance training 3-5 days/week on GLP-1 agonists preserved or even gained lean tissue (Tinsley and Nadolsky, 2025)
- Locatelli et al. (2024) concluded resistance exercise is the primary evidence-based strategy for optimizing body composition during incretin therapy
- The SLIM LIVER secondary analysis found semaglutide reduced psoas muscle volume by 9.3%, but physical function was maintained (Ditzenberger et al., 2025)
- Jensen et al. (2026) found combined exercise plus GLP-1 treatment improved physical fitness more than either intervention alone
How Much Lean Mass Does Semaglutide Actually Cost?
The baseline question for anyone starting semaglutide is: how much muscle do you actually lose on GLP-1 drugs? The answer varies substantially depending on the study, the measurement method, and whether the trial included any exercise component.
Bikou et al. (2024) conducted the most comprehensive systematic review to date, analyzing six randomized controlled trials. They found that semaglutide produced significant weight loss primarily through fat mass reduction, but lean mass reductions were "particularly evident in larger trials." The proportion of lean mass relative to total body mass actually increased in most studies, suggesting the body was becoming leaner overall even while losing some muscle.[1]
The SEMALEAN study (Alissou et al., 2026) provides the most detailed longitudinal data. This prospective study followed 106 patients with obesity (mean BMI 46.3 kg/m2) treated with semaglutide 2.4 mg for 12 months, measuring body composition by DXA at baseline, 7 months, and 12 months. Total fat mass decreased 14% at 7 months and 18% at 12 months. Lean mass dropped 3 kg at 7 months but stabilized from month 7 to 12.[2]
The stabilization finding is critical. It suggests the lean mass loss is not progressive and endless. The body appears to reach a new equilibrium where further weight loss comes primarily from fat. Whether that equilibrium is influenced by physical activity was not specifically tested in SEMALEAN, but it aligns with what the exercise data show.
What Happens to Muscle Function?
Muscle mass and muscle function are not the same thing. The SEMALEAN study made this distinction explicitly: despite the initial lean mass decline, handgrip strength improved by 4.5 kg at 12 months, and the prevalence of sarcopenic obesity dropped from 49% at baseline to 33% at 12 months.[2]
Ditzenberger et al. (2025) found a similar dissociation in the SLIM LIVER study, a secondary analysis of semaglutide's effects on muscle structure and function. Low-dose semaglutide produced a 9.3% decrease in psoas muscle volume, yet physical function was maintained.[3] The psoas is a deep core muscle that is particularly sensitive to metabolic changes, so a 9.3% volume reduction there does not necessarily translate to proportional strength loss.
Choi et al. (2024) offered a potential explanation at the cellular level. Their research found that semaglutide-induced weight loss improves mitochondrial energy efficiency in skeletal muscle.[4] In other words, the remaining muscle may work better even if there is less of it. This does not eliminate the concern about lean mass loss, but it complicates the simple narrative that less muscle always means worse function.
Jeromson et al. (2025) added nuance from animal data, finding that semaglutide impacts skeletal muscle to a similar extent as equivalent caloric restriction in mice. This suggests the muscle loss is driven by energy deficit rather than a direct drug effect on muscle tissue.[5] If true, that means anything that protects muscle during caloric restriction should also protect it during semaglutide treatment.
The Evidence for Resistance Training as a Countermeasure
Locatelli et al. (2024) published the most directly relevant review in Diabetes Care, asking whether resistance exercise can optimize body composition changes during incretin-based weight loss pharmacotherapy. Their conclusion: resistance exercise is the primary evidence-based strategy for preserving lean mass during GLP-1 agonist treatment.[6]
The evidence base is still building. Most large semaglutide trials (STEP-1 through STEP-5) did not include structured exercise programs, which means the lean mass losses reported in those trials represent what happens without exercise as a deliberate intervention. When exercise is added, the picture changes.
Tinsley and Nadolsky (2025) published a case series in SAGE Open Medical Case Reports describing patients who prioritized lean tissue preservation during GLP-1 and GLP-1/GIP receptor agonist treatment. The patients engaged in intentional exercise 4-7 days per week, including resistance training 3-5 days per week. Results varied: one patient lost 8.7% of weight as lean tissue (well below the 26-40% range from uncontrolled trials), while two patients actually increased lean soft tissue during treatment.[7]
A case series of three patients is not a controlled trial. But the signal is consistent with the broader exercise physiology literature: resistance training sends an anabolic stimulus that counteracts the catabolic effects of energy deficit. The question is magnitude, not direction.
Jensen et al. (2026) provided stronger evidence in Sports Medicine, studying physical fitness outcomes with exercise and GLP-1 receptor agonist treatment alone or combined. The combination improved physical fitness more than either intervention alone.[8] Jensen et al. (2024) also studied bone health after exercise alone, GLP-1 treatment alone, or the combination, finding that the bone density concerns on GLP-1s may also be mitigated by exercise.[9]
What Kind of Exercise? How Much?
Codella, Senesi, and Luzi (2025) addressed this directly in Frontiers in Clinical Diabetes and Healthcare, arguing that resistance training, not aerobic exercise, should be prioritized for patients on GLP-1 agonists. Their review of the evidence found that resistance exercise specifically targets the lean mass preservation mechanism, while aerobic exercise primarily complements the cardiovascular and metabolic benefits of GLP-1 treatment.[10]
Barana et al. (2025) reviewed the combined role of nutrition and physical activity in optimizing outcomes during GLP-1 therapy. They emphasized that resistance training and adequate protein intake are complementary strategies, not alternatives. The exercise provides the stimulus for muscle protein synthesis; the protein provides the substrate. Without both, lean mass preservation is compromised.[11]
The case series from Tinsley and Nadolsky (2025) described protocols of 3-5 resistance training sessions per week with full-body compound movements.[7] This aligns with general exercise physiology recommendations for muscle preservation during caloric deficit: compound lifts (squats, deadlifts, presses, rows), progressive overload, and sufficient training volume distributed across multiple weekly sessions.
There is no randomized controlled trial comparing specific resistance training protocols in semaglutide-treated patients. The recommendations are extrapolated from the weight loss surgery literature and from general caloric restriction studies, where resistance training consistently outperforms aerobic exercise for lean mass retention. Given that Jeromson et al. (2025) found semaglutide's muscle effects are similar to caloric restriction, this extrapolation is reasonable.[5]
The Sarcopenia Risk in Context
Pantazopoulos et al. (2025) published a narrative review in Diabetes Research and Clinical Practice titled "GLP-1 receptor agonists and sarcopenia: Weight loss at a cost?" They argued that the lean mass losses observed in GLP-1 trials warrant clinical attention, particularly in older adults and in patients who are already sarcopenic at baseline.[12]
The risk is not uniform across populations. A 25-year-old with obesity who loses 3 kg of lean mass has a very different clinical trajectory than a 70-year-old with sarcopenic obesity who loses the same amount. The SEMALEAN data showed that sarcopenic obesity prevalence actually decreased from 49% to 33% during treatment, suggesting that for patients starting with high body fat, the net effect of semaglutide on body composition can be positive even with some lean mass loss.[2]
Several factors compound the risk in older populations. Age-related anabolic resistance means older adults require a stronger stimulus (more sets, more protein per meal) to achieve the same muscle protein synthesis response as younger adults. Reduced appetite on semaglutide makes hitting protein targets harder. And many older adults on GLP-1 agonists have comorbidities that limit exercise intensity or frequency. Pantazopoulos et al. (2025) recommended that clinicians screen for sarcopenia before initiating GLP-1 therapy in patients over 65 and implement structured exercise programs from day one rather than waiting for visible muscle loss.[12]
The cosmetic effects of rapid GLP-1 weight loss get more attention in popular media, but the sarcopenia question has greater clinical implications. A patient who loses 15% body weight but preserves muscle function is in a fundamentally different position than one who loses 15% body weight and cannot get out of a chair. Resistance training is the most reliable way to stay in the first category.
The Practical Challenge: Appetite Suppression and Training Performance
One underappreciated challenge is that semaglutide's appetite suppression can make resistance training harder. Training on minimal calories is less productive: the body has fewer resources for muscle protein synthesis, recovery is slower, and subjective energy levels are lower. This creates a tension at the heart of the strategy. The drug that causes the lean mass problem also makes the solution harder to execute.
Barana et al. (2025) specifically addressed the nutritional timing dimension. They suggested distributing protein intake across multiple meals with at least 20-30 g per serving to maximize the muscle protein synthesis response, and timing a protein-rich meal within two hours after resistance training.[11] For patients with severe appetite suppression, liquid protein sources (shakes, broths) may be better tolerated than solid food.
Training intensity also matters more than training volume in a caloric deficit. Maintaining the load on the bar (even if total volume decreases) sends a stronger muscle-preservation signal than high-volume, low-intensity work. This is consistent with general resistance training recommendations during weight loss: prioritize intensity over volume when recovery is limited.
What We Do Not Know
No large randomized controlled trial has directly compared semaglutide plus resistance training versus semaglutide alone with lean mass as the primary endpoint. NCT06885736 is currently registered on ClinicalTrials.gov to study lean mass preservation during GLP-1 treatment with exercise, but results are not yet available. Until that type of trial reports, the evidence for resistance training as a countermeasure rests on:
- Exercise physiology principles applied to the GLP-1 context
- Small case series showing lean mass preservation with structured training
- Reviews concluding that resistance exercise is the best available strategy
- The Jeromson et al. (2025) finding that semaglutide's muscle effects mirror caloric restriction, for which resistance training is an established countermeasure
The dose-response relationship is unknown. Whether two sessions per week is sufficient, or whether four to five sessions are needed to meaningfully shift the lean mass ratio, has not been tested. The optimal protein intake to complement resistance training on semaglutide is also unstudied in a controlled setting, though the protein intake data from general weight loss research suggests 1.2-1.6 g/kg/day as a reasonable target.
The interaction between semaglutide's body composition effects and exercise may also vary by dose. The 0.5 mg diabetes dose, the 1.0 mg dose, and the 2.4 mg weight loss dose produce different magnitudes of energy deficit. Whether the exercise countermeasure scales proportionally is an open question.
The Bottom Line
Resistance training is the most evidence-supported strategy for preserving lean mass during semaglutide treatment. The SEMALEAN study shows lean mass loss stabilizes by month 7 and muscle function can actually improve. Case series data suggest structured resistance training 3-5 days per week can shift the ratio of fat-to-lean mass loss dramatically. No large RCT has confirmed this directly for semaglutide, but the mechanistic rationale from Jeromson et al. (2025) and the exercise physiology literature make a strong case.